Tom 20, Nr 4 (2024)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2025-02-13
Wyświetlenia strony
242
Wyświetlenia/pobrania artykułu
62
Przegląd piśmiennictwa
DOI: 10.5603/ppn.103875
Pol. Przegl. Neurol 2024;20(4):242-245.
Streszczenie
Brak
Referencje
- Szczudlik P, Sobieszczuk E, Walczak M, et al. Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients - real world data. Neurol Neurochir Pol. 2024; 58(5): 498–502.
- Yan C, Yue Y, Guan Y, et al. Batoclimab Study Team. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2024 [Epub ahead of print]; 81(4): 336–345.
- Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. EPIDYS Study Group. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024; 23(4): 393–403.
- Gianferrari G, Cuoghi Costantini R, Crippa V, et al. Co-ALS Investigators Group. Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial. Brain Commun. 2024; 6(5): fcae304.
- Groulx-Boivin E, Oliveira-Carneiro A, Carlson H, et al. Macrostructural brain abnormalities in spinal muscular atrophy: a case-control study. Neurol Genet. 2024; 10(5): e200193.
- Maya-González C, Tettamanti G, Taylan F, et al. Cancer risk in patients with muscular dystrophy and myotonic dystrophy: a register-based cohort study. Neurology. 2024; 103(8): e209883.
- Kristensen FPB, Christensen DH, Callaghan BC, et al. Lipid Levels and Risk of Diabetic Polyneuropathy in 2 Danish Type 2 Diabetes Cohorts. Neurology. 2024; 103(1): e209538.
